Form 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES EXCHANGE ACT OF 1934
For the month of August 2010
Commission File Number: 001-33623
WuXi PharmaTech (Cayman) Inc.
288 Fute Zhong Road, Waigaoqiao Free Trade Zone
Shanghai 200131
People’s Republic of China
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-N/A
WuXi PharmaTech (Cayman) Inc.
Form 6-K
| Page | ||
| Signature | 3 | |
| Exhibit 99.1 — Press Release | 4 | |
| PRESS RELEASE DATED August 2, 2010 | ||
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| WuXi PharmaTech (Cayman) Inc. | ||
| By: | /S/ EDWARD HU | |
| Name: | Edward Hu | |
| Title: | Chief Financial Officer | |
Date: August 5, 2010
3
WuXi PharmaTech Announces Second-Quarter 2010 Results
SHANGHAI, China, August 2, 2010 /Xinhua-PRNewswire/ — WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States, today announced its financial results for its second quarter ending June 30, 2010.
Highlights
| • | Second-Quarter 2010 Net Revenues Increased 21% Year Over Year to $81.0 Million |
| • | Laboratory Services Net Revenues Grew 18% Year Over Year to $72.6 Million |
| • | China-Based Laboratory Services Net Revenues Increased 18% Year Over Year to $52.7 Million |
| • | U.S.-Based Laboratory Services Net Revenues Increased 19% Year Over Year to $19.9 Million |
| • | Manufacturing Services Net Revenues Grew 55% Year Over Year to $8.4 Million |
| • | GAAP Diluted Earnings Per ADS Declined 8% Year Over Year to 18 Cents, Reflecting Non-Recurring Deal Costs Associated With the WuXi – Charles River Merger of 4 Cents Per Share |
| • | Non-GAAP Diluted Earnings Per ADS Increased 10% Year Over Year to 27 Cents |
| • | Company Increases Full-Year 2010 Guidance for Operating Income to 15-20% Growth, Reconfirms Remaining Full-Year 2010 Guidance |
Management Comment
“WuXi had a strong second-quarter, with results in line with, or at the upper end of ranges for, results provided in our announcement on July 15, 2010,” said Dr. Ge Li. “We achieved 21% year-over-year revenue growth. That revenue growth was broad-based, with each of our businesses contributing at least 18% year-over-year revenue growth. Gross margin and operating margin were also strong. We met or exceeded our projections for second-quarter 2010 performance. We are increasing our guidance for operating income for full-year 2010 and reconfirming the remainder of the increased full-year 2010 financial guidance that we announced on July 15.
“On July 29, WuXi announced that we and Charles River Laboratories would not proceed with our planned combination due to insufficient support among Charles River shareholders,” Dr. Li continued. “We received a breakup fee of $30 million, which we will record in the third quarter and which more than offsets our transaction-related expenses. This outcome will have no effect on our strategy or operations, and we remain committed to our goal of building a broad, integrated platform of R&D services. This platform will help our customers to improve the success of discovery and shorten the development time of new products to meet unmet patient needs. This open-access service platform will allow customers to use the entire portfolio of our services or any portion of it.
“WuXi is achieving strong current financial performance while making the investments to continuously build capabilities and capacities in our core Laboratory Services business and our new large-scale manufacturing and toxicology businesses. With a sound strategy, market-leading position, and talented people, our future remains bright,” Dr. Li concluded.
4
GAAP Results
Second-quarter 2010 net revenues increased 21% year over year to $81.0 million due to 18% growth in Laboratory Services net revenues and 55% growth in Manufacturing Services net revenues. Revenue growth in Laboratory Services was strong in both discovery chemistry and downstream services and in both China and the United States. Revenue growth in Manufacturing Services was driven by increasing demand for clinical-trial supplies.
Second-quarter 2010 GAAP gross profit increased 23% year over year to $33.2 million due to strong contributions from both Laboratory Services and Manufacturing Services, driven by revenue growth and gross-margin improvement in both segments. Second-quarter 2010 GAAP gross margin improved year over year due to improved project mix in both Laboratory Services and Manufacturing Services and benefits of Lean Six Sigma programs undertaken in the United States. This gross margin improvement occurred in spite of a larger contribution from the relatively lower-margin Manufacturing Services business and increased expenses related to the ramp-up of the Suzhou toxicology facility.
Second-quarter 2010 GAAP operating income grew 18% year over year to $16.1 million, driven by the 23% increase in gross profit and lower operating expenses driven by cost control, offset by $2.9 million of non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories, mostly third-party professional service fees.
Second-quarter 2010 GAAP net income declined 6% year over year to $13.8 million due to an unfavorable change in other income (expenses) net and higher taxes, offset by the 18% increase in operating income, which was impacted by $2.9 million of non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories. In second-quarter 2009, other income (expenses) net included gains from settlement of escrow shares of $1.7 million associated with the AppTec acquisition. The year-over-year increase in tax expense was mainly driven by higher 2010 China statutory tax rates compared to 2009 as a result of the income tax transitional phase-out rules in China.
Second-quarter 2010 GAAP diluted earnings per ADS decreased 8% to 18 cents, mainly due to the 6% decrease in net income. Non-recurring deal costs associated with the terminated WuXi – Charles River merger had an impact of 4 cents per share.
Non-GAAP Results
Non-GAAP financial results excluded the impact of share-based compensation expenses, amortization of acquired intangible assets and the associated deferred tax impact, and non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories.
Second-quarter 2010 non-GAAP gross profit increased 23% year over year to $35.0 million, due to strong contributions from both Laboratory Services and Manufacturing Services, driven by revenue growth and gross-margin improvement in both segments. Second-quarter 2010 non-GAAP gross margin improved year over year due to improved project mix in both Laboratory Services and Manufacturing Services and benefits of Lean Six Sigma programs undertaken in the United States. This gross margin improvement occurred in spite of a larger contribution from the relatively lower-margin Manufacturing Services business and increased expenses related to the ramp-up of the Suzhou toxicology facility.
Second-quarter 2010 non-GAAP operating income increased 32% year over year to $22.5 million, driven by the 23% increase in gross profit and lower operating expenses driven by cost control.
Second-quarter 2010 non-GAAP net income grew 12% year over year to $19.9 million due to the 32% increase in operating income, offset by an unfavorable change in other income (expenses) net and higher taxes. In second-quarter 2009, other income (expenses) net in second-quarter 2009 included
5
gains from settlement of escrow shares of $1.7 million associated with the AppTec acquisition. The year-over-year increase in tax expense was mainly driven by higher 2010 China statutory tax rates compared to 2009 as a result of the income tax transitional phase-out rules in China.
Second-quarter 2010 non-GAAP diluted earnings per ADS increased 10% to 27 cents, mainly due to the 12% increase in net income.
2010 Financial Guidance
The Company is pleased to increase its guidance for full-year 2010 operating income and to reconfirm the rest of its previous financial guidance for 2010 provided on July 15, 2010. All comparative comments refer to year-over-year comparisons. The Company’s current guidance for 2010 is as follows:
| • | Total net revenues of $320-325 million, which represents 19-20% growth |
| • | Growth in net revenues of China-based Laboratory Services of 16-18% |
| • | Double-digit growth in net revenues of U.S.-based Laboratory Services |
| • | Growth of net revenues of Manufacturing Services of at least 70% |
| • | A decline in GAAP and non-GAAP gross margins of two to three percentage points |
| • | Growth in non-GAAP operating income of 15-20%, compared to 10-15% in previous guidance |
| • | Capital expenditures of about $50 million |
| • | Effective tax rate of 13-15%, excluding one-time transaction costs |
The Company provides the following guidance for third-quarter 2010 performance:
| • | Total net revenues of $78-$80 million |
| • | Net revenues of China-based Laboratory Services of $55-$56 million, representing 15-17% growth |
| • | A decline in gross margin as expected and in line with our full-year financial guidance |
“Strong trends toward greater outsourcing and offshoring of pharmaceutical R&D services will continue for years,” Dr. Li concluded. “As the leading China-based CRO, WuXi is well positioned to benefit from these trends. WuXi has excellent prospects to sustain strong revenue and income growth for many years to come.”
6
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONSOLIDATED BALANCE SHEETS
(in thousands of U.S. dollars, except ordinary share, ADS and par value data)
| June 30, 2010 | December 31, 2009 | |||||
Assets: | ||||||
Current assets: | ||||||
Cash and cash equivalents | 79,122 | 80,510 | ||||
Restricted cash | 1,481 | 1,358 | ||||
Short-term investment | 22,170 | 22,083 | ||||
Accounts receivable, net | 57,712 | 45,817 | ||||
Inventories | 11,281 | 14,276 | ||||
Prepaid expenses and other current assets | 9,892 | 10,125 | ||||
Total current assets | 181,658 | 174,169 | ||||
Non-current assets: | ||||||
Goodwill | 23,956 | 23,956 | ||||
Property, plant and equipment, net | 189,366 | 181,830 | ||||
Intangible assets, net | 5,286 | 6,634 | ||||
Prepaid land use rights | 5,278 | 5,308 | ||||
Deferred tax assets | 9,767 | 9,514 | ||||
Other non-current assets | 5,028 | 5,890 | ||||
Total non-current assets | 238,681 | 233,132 | ||||
Total assets | 420,339 | 407,301 | ||||
Liabilities and Equity: | ||||||
Current liabilities: | ||||||
Short-term and current portion of long-term debt | 10,257 | 34,415 | ||||
Accounts payable | 13,497 | 14,356 | ||||
Accrued expenses | 16,893 | 17,072 | ||||
Deferred revenue | 6,509 | 4,554 | ||||
Advanced subsidies | 2,241 | 2,800 | ||||
Other taxes payable | 2,114 | 2,901 | ||||
Other current liabilities | 6,423 | 4,239 | ||||
Liabilities of discontinued operations (Note 1) | — | — | ||||
Total current liabilities | 57,934 | 80,337 | ||||
Non-current liabilities: | ||||||
Long-term debt, excluding current portion | 1,985 | 2,115 | ||||
Advanced subsidies | 1,283 | 1,420 | ||||
Convertible notes | 35,864 | 35,864 | ||||
Other non-current liabilities | 6,628 | 7,432 | ||||
Total non-current liabilities | 45,760 | 46,831 | ||||
Total liabilities | 103,694 | 127,168 | ||||
Equity: | ||||||
Ordinary shares ($0.02 par value, 5,002,550,000 authorized, 556,144,592 and 550,609,256 issued and outstanding as of June 30, 2010, and December 31, 2009, respectively) | 11,123 | 11,012 | ||||
Additional paid-in capital | 326,247 | 320,672 | ||||
Accumulated deficit | (39,355 | ) | (68,631 | ) | ||
Accumulated other comprehensive income | 18,630 | 17,080 | ||||
Total equity | 316,645 | 280,133 | ||||
Total liabilities and equity | 420,339 | 407,301 | ||||
7
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands of U.S. dollars, except ADS data and per ADS data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||
| 2010 | 2009 | % Change | 2010 | 2009 | % Change | |||||||||||||
Net revenues: | ||||||||||||||||||
Laboratory Services | 72,581 | 61,489 | 18 | % | 139,579 | 118,084 | 18 | % | ||||||||||
Manufacturing Services | 8,456 | 5,464 | 55 | % | 22,060 | 8,017 | 175 | % | ||||||||||
Total net revenues | 81,037 | 66,953 | 21 | % | 161,639 | 126,101 | 28 | % | ||||||||||
Cost of revenues: | ||||||||||||||||||
Laboratory Services | (41,171 | ) | (35,204 | ) | 17 | % | (80,456 | ) | (69,059 | ) | 17 | % | ||||||
Manufacturing Services | (6,659 | ) | (4,670 | ) | 43 | % | (17,558 | ) | (6,643 | ) | 164 | % | ||||||
Total cost of revenues | (47,830 | ) | (39,874 | ) | 20 | % | (98,014 | ) | (75,702 | ) | 29 | % | ||||||
Gross profit: | ||||||||||||||||||
Laboratory Services | 31,410 | 26,285 | 19 | % | 59,123 | 49,025 | 21 | % | ||||||||||
Manufacturing Services | 1,797 | 795 | 126 | % | 4,502 | 1,374 | 228 | % | ||||||||||
Total gross profit | 33,207 | 27,080 | 23 | % | 63,625 | 50,399 | 26 | % | ||||||||||
Operating expenses: | ||||||||||||||||||
Selling and marketing expenses | (2,333 | ) | (2,413 | ) | (3 | %) | (4,615 | ) | (3,747 | ) | 23 | % | ||||||
General and administrative expenses | (14,785 | ) | (11,031 | ) | 34 | % | (25,485 | ) | (22,741 | ) | 12 | % | ||||||
Total operating expenses | (17,118 | ) | (13,444 | ) | 27 | % | (30,100 | ) | (26,488 | ) | 14 | % | ||||||
Operating income | 16,089 | 13,636 | 18 | % | 33,525 | 23,911 | 40 | % | ||||||||||
Other income (expenses), net: | ||||||||||||||||||
Other income (expenses), net | 433 | 2,975 | (85 | %) | 616 | 6,368 | (90 | %) | ||||||||||
Interest income (expenses), net | 159 | 144 | 11 | % | 257 | 94 | 173 | % | ||||||||||
Total other income (expenses), net | 592 | 3,119 | (81 | %) | 873 | 6,462 | (86 | %) | ||||||||||
Income before income taxes | 16,681 | 16,755 | 0 | % | 34,398 | 30,373 | 13 | % | ||||||||||
Income tax (expenses) benefit | (2,923 | ) | (2,069 | ) | (41 | %) | (5,122 | ) | (3,952 | ) | 30 | % | ||||||
Net income | 13,758 | 14,686 | (6 | %) | 29,276 | 26,421 | 11 | % | ||||||||||
Basic net earnings per ADS: | 0.20 | 0.22 | (8 | %) | 0.42 | 0.39 | 8 | % | ||||||||||
Diluted net earnings per ADS: | 0.18 | 0.20 | (8 | %) | 0.39 | 0.36 | 9 | % | ||||||||||
Weighted average ADS outstanding—basic | 69,416,476 | 67,944,436 | 69,246,669 | 67,469,104 | ||||||||||||||
Weighted average ADS outstanding—diluted | 74,591,847 | 73,152,798 | 74,465,668 | 73,356,170 | ||||||||||||||
| * | Not meaningful |
8
WUXI PHARMATECH (CAYMAN) INC.
RECONCILIATION OF GAAP TO NON-GAAP
(in thousands of U.S. dollars, except ADS data and per ADS data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||||
| 2010 | 2009 | % | 2010 | 2009 | % | |||||||||||||
GAAP gross profit | 33,207 | 27,080 | 23 | % | 63,625 | 50,399 | 26 | % | ||||||||||
GAAP gross margin | 41 | % | 40 | % | 39 | % | 40 | % | ||||||||||
Adjustments: | ||||||||||||||||||
Share-based compensation | 997 | 562 | 1,885 | 1,153 | ||||||||||||||
Amortization of acquired intangible assets | 764 | 764 | 1,528 | 1,528 | ||||||||||||||
Non-GAAP gross profit | 34,968 | 28,406 | 23 | % | 67,038 | 53,080 | 26 | % | ||||||||||
Non-GAAP gross margin | 43 | % | 42 | % | 41 | % | 42 | % | ||||||||||
GAAP operating income | 16,089 | 13,636 | 18 | % | 33,525 | 23,911 | 40 | % | ||||||||||
GAAP operating margin | 20 | % | 20 | % | 21 | % | 19 | % | ||||||||||
Adjustments: | ||||||||||||||||||
Share-based compensation | 2,748 | 2,659 | 5,069 | 4,658 | ||||||||||||||
Amortization of acquired intangible assets | 764 | 764 | 1,528 | 1,528 | ||||||||||||||
Non-recurring deal cost | 2,933 | — | * | 2,933 | ||||||||||||||
Non-GAAP operating income | 22,534 | 17,059 | 32 | % | 43,055 | 30,097 | 43 | % | ||||||||||
Non-GAAP operating margin | 28 | % | 25 | % | 27 | % | 24 | % | ||||||||||
GAAP net income | 13,758 | 14,686 | (6 | %) | 29,276 | 26,421 | 11 | % | ||||||||||
GAAP net margin | 17 | % | 22 | % | 18 | % | 21 | % | ||||||||||
Adjustments: | ||||||||||||||||||
Share-based compensation | 2,748 | 2,659 | 5,069 | 4,658 | ||||||||||||||
Amortization of acquired intangible assets | 764 | 764 | 1,528 | 1,528 | ||||||||||||||
Deferred tax impact related to acquired intangible assets | (296 | ) | (296 | ) | (592 | ) | (592 | ) | ||||||||||
Non-recurring deal costs | 2,933 | — | * | 2,933 | — | * | ||||||||||||
Non-GAAP net income | 19,907 | 17,813 | 12 | % | 38,214 | 32,015 | 19 | % | ||||||||||
Non-GAAP net margin | 25 | % | 27 | % | 24 | % | 25 | % | ||||||||||
GAAP net income | 13,758 | 14,686 | (6 | %) | 29,276 | 26,421 | 11 | % | ||||||||||
Add back: | ||||||||||||||||||
Depreciation and amortization | 6,851 | 5,620 | 22 | % | 13,230 | 10,627 | 24 | % | ||||||||||
Interest (income) expenses, net | (159 | ) | (144 | ) | 11 | % | (257 | ) | (94 | ) | 173 | % | ||||||
Income tax expenses | 2,923 | 2,069 | 41 | % | 5,122 | 3,952 | 30 | % | ||||||||||
EBITDA | 23,373 | 22,231 | 5 | % | 47,371 | 40,906 | 16 | % | ||||||||||
Adjustments: | ||||||||||||||||||
Share-based compensation | 2,748 | 2,659 | 3 | % | 5,069 | 4,658 | 9 | % | ||||||||||
Mark-to-market gains (losses) from foreign-currency forward contracts | (200 | ) | 401 | * | 416 | (2,219 | ) | * | ||||||||||
Non-recurring deal costs | 2,933 | — | * | 2,933 | * | |||||||||||||
Impairment charge from discontinued operations | — | — | — | — | * | |||||||||||||
Adjusted EBITDA | 28,854 | 25,291 | 14 | % | 55,789 | 43,345 | 29 | % | ||||||||||
Income attributable to holders of ADS (Non-GAAP): | ||||||||||||||||||
Basic | 19,907 | 17,813 | 12 | % | 38,214 | 32,015 | 19 | % | ||||||||||
Diluted | 19,907 | 17,813 | 12 | % | 38,214 | 32,015 | 19 | % | ||||||||||
Basic earnings per ADS (Non-GAAP) | 0.29 | 0.26 | 9 | % | 0.55 | 0.47 | 16 | % | ||||||||||
Diluted earnings per ADS (Non-GAAP) | 0.27 | 0.24 | 10 | % | 0.51 | 0.44 | 18 | % | ||||||||||
Weighted average ADS outstanding—basic | 69,416,476 | 67,944,436 | 69,246,669 | 67,469,104 | ||||||||||||||
Weighted average ADS outstanding—diluted | 74,591,847 | 73,152,798 | 74,465,668 | 73,356,170 | ||||||||||||||
| * | Not meaningful |
WUXI PHARMATECH (CAYMAN) INC.
REVENUE BREAKDOWN
(in thousands of U.S. dollars)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2010 | 2009 | % | 2010 | 2009 | % | |||||||||
Net revenues: | ||||||||||||||
China-based Laboratory Services | 52,673 | 44,810 | 18 | % | 102,645 | 86,458 | 19 | % | ||||||
U.S.-based Laboratory Services | 19,908 | 16,679 | 19 | % | 36,934 | 31,626 | 17 | % | ||||||
Subtotal | 72,581 | 61,489 | 18 | % | 139,579 | 118,084 | 18 | % | ||||||
China-based Manufacturing Services | 8,456 | 5,464 | 55 | % | 22,060 | 8,017 | 175 | % | ||||||
Total net revenues | 81,037 | 66,953 | 21 | % | 161,639 | 126,101 | 28 | % | ||||||
Conference Call
WuXi will hold a conference call at 10:00 am EDT to discuss the results and the outlook for WuXi’s business. The conference call may be accessed by calling:
United States: 1-866-519-4004
China (Landline): 800-819-0121
China (Mobile): 400-620-8038
Hong Kong: 800-930-346
United Kingdom: 0-808-234-6646
International: +65-6723-9381
Conference ID: 90840146
Web PIN: 8656
A replay will be available two hours after the call’s completion at:
United States: 1-866-214-5335
China North: 10-800-714-0386
10
China South: 10-800-140-0386
Hong Kong: 800-901-596
United Kingdom: 0-800-731-7846
International: +61-2-8235-5000
Passcode: 90840146
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech’s website athttp://www.wuxiapptec.com.
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech’s services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech’s operating subsidiaries are known as WuXi AppTec. For more information, please visit:http://www.wuxiapptec.com.
Use of Non-GAAP Financial Measures
We have provided second-quarter 2009 and 2010 gross profit, gross margin, operating income, operating margin, and earnings per ADS on a non-GAAP basis, which excludes share-based compensation expenses, amortization of acquired intangible assets and associated deferred tax impact, and non-recurring deal costs relating to the previously proposed combination with Charles River Laboratories. We believe both management and investors benefit from referring to these non-GAAP financial measures in assessing our financial performance and liquidity and when planning and forecasting future periods. These non-GAAP operating measures are useful for understanding and assessing underlying business performance and operating trends. We expect to continue providing gross profit, operating income, and diluted earnings per ADS on a non-GAAP basis using a consistent method on a quarterly basis. You should not view non-GAAP results on a stand-alone basis or as a substitute for results under GAAP, or as being comparable to results reported or forecasted by other companies.
Cautionary Note Regarding Forward-Looking Statements
Statements in this release contain “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including those with respect to our financial guidance for third-quarter 2010 and full-year 2010 and prospects generally, anticipated customer benefits of our integrated R&D platform, expected strong performance of all our businesses and industry trends favoring outsourcing and offshoring R&D, are not historical facts but instead represent only our belief regarding future events, many of which, by their nature, are inherently uncertain and outside of our control. Our actual results and financial condition and other circumstances may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Among other factors, potential customer, employee and management distraction following the termination of our proposed combination with Charles River Laboratories, continued uncertainty in the global economy, the pressures being felt by our customers, and pharmaceutical industry consolidation may adversely impact our business and the trends for outsourced and offshored R&D and manufacturing for longer than expected or more severely than expected; we may be unable to successfully make our planned investments and capital expenditures on a timely basis, these investments may not yield the desired results, and we may need to modify the nature
11
and level of our investments and capital expenditures; pharmaceutical companies may not change their business models as expected or in a manner favorable to us; we may fail to capitalize on the opportunities presented; we may not maintain our preferred provider status with our clients and may be unable to successfully expand our capabilities to meet client needs. In addition, other factors that could cause our actual results to differ from what we currently anticipate include failure to generate sufficient future cash flows or to secure any required future financing on acceptable terms or at all; failure to retain key personnel; effective integration of continuing products and services from AppTec; our reliance on a limited number of customers to continue to account for a high percentage of our revenues; risk of payment failure by any of our large customers, which could significantly harm our cash flows and profitability; dependence upon the continued service of our senior management and key scientific personnel; our ability to retain our existing customers or expand our customer base; and future regulatory or legislative actions. For additional information on these and other important factors that could adversely affect our business, financial condition, results of operations and prospects, see “Risk Factors” beginning on page 6 of our 2009 Annual Report on Form 20-F filed with and available on the Securities and Exchange Commission’s website at http://www.sec.gov. All projections in this release are based on limited information currently available to us, which is subject to change. Although these projections and the factors influencing them will likely change, we undertake no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release, except as required by law. Such information speaks only as of the date of this release.
For more information, please contact:
WuXi PharmaTech (Cayman) Inc.
Ronald Aldridge (for investors)
Director of Investor Relations
Tel: +1-201-585-2048
Email:ir@wuxiapptec.com
Stephanie Liu (for the media)
WuXi PharmaTech (Cayman) Inc.
Tel: +86-21-5046-4362
Email:pr@wuxiapptec.com
/Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO
PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840/
/Web site: http://www.wuxiapptec.com/
(WX)
12
